Dave Clennell joins DxS
This article was originally published in Clinica
Molecular diagnostics company DxS has appointed Dave Clennell director of quality. Mr Clennell has worked in the healthcare industry for 30 years, and was previously director of quality for Lombard Medical Technologies. He has also been employed by Johnson & Johnson, Genzyme and SmithKline Beecham Pharmaceuticals. Manchester, UK-based DxS plans to submit its TheraScreen K-RAS mutation kit to the US FDA "imminently" – it CE marked the test for sale in Europe in January 2008. The diagnostic detects mutations in the KRAS gene that are linked with decreased efficacy of EGFR inhibitors like Amgen's Vectibix (panitumumab), which are used to treat colorectal cancer.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.